Home » BIODIEM TO BEGIN DIABETIC BLINDNESS TRIAL
BIODIEM TO BEGIN DIABETIC BLINDNESS TRIAL
BioDiem has received regulatory approval to begin a Phase I/II clinical trial for its peptide BDM-E in patients with diabetic macula oedema, a leading cause of blindness.
BDM-E is a potential treatment for the two major causes of blindness -- diabetic retinopathy and age-related macular degeneration. It is a small synthetic peptide that can stimulate growth of new retinal pigmented epithelial cells and inhibits the growth of choroidal endothelial cells associated with unwanted neovascularisation.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May